{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:36:58Z","timestamp":1780915018239,"version":"3.54.1"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117168","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T15:06:57Z","timestamp":1734275217000},"page":"117168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Chemical dissection of selective myeloid leukemia-1 inhibitors: How they were found and evolved"],"prefix":"10.1016","volume":"283","author":[{"given":"Luyao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmech.2024.117168_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"issue":"5381","key":"10.1016\/j.ejmech.2024.117168_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.281.5381.1309","article-title":"Mitochondria and apoptosis","volume":"281","author":"Green","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/15548627.2020.1860542","article-title":"Targeting MCL1 to induce mitophagy is a potential therapeutic strategy for alzheimer disease","volume":"17","author":"Cen","year":"2021","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117168_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0000000000000408","article-title":"BCL-2 inhibitors, present and future","volume":"25","author":"Ryan","year":"2019","journal-title":"Cancer J."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/cdd.2008.137","article-title":"Bcl-2 inhibitors: small molecules with a big impact on cancer therapy","volume":"16","author":"Vogler","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2024.117168_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.704547","article-title":"Physiological functions of mcl-1: insights from genetic mouse models","volume":"9","author":"Chin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"7283","key":"10.1016\/j.ejmech.2024.117168_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"issue":"7391","key":"10.1016\/j.ejmech.2024.117168_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117168_bib18","doi-asserted-by":"crossref","DOI":"10.4149\/neo_2023_221217N1185","article-title":"Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia","author":"Wang","year":"2023","journal-title":"neo"},{"key":"10.1016\/j.ejmech.2024.117168_bib19","first-page":"2022","article-title":"Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in mice","volume":"14","author":"Khan","year":"2022","journal-title":"bioRxiv September"},{"issue":"17","key":"10.1016\/j.ejmech.2024.117168_bib20","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2007-11-126664","article-title":"A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML","volume":"113","author":"Breitenbuecher","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejmech.2024.117168_bib21","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"issue":"22","key":"10.1016\/j.ejmech.2024.117168_bib22","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1016\/j.molcel.2021.09.015","article-title":"Proteome-wide mapping of short-lived proteins in human cells","volume":"81","author":"Li","year":"2021","journal-title":"Mol. Cell"},{"issue":"31","key":"10.1016\/j.ejmech.2024.117168_bib24","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","article-title":"MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol","volume":"23","author":"Domina","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.117168_bib25","first-page":"2024","article-title":"Confounding factors in targeted degradation of short-lived proteins","volume":"22","author":"Vetma","year":"2024","journal-title":"bioRxiv February"},{"issue":"15","key":"10.1016\/j.ejmech.2024.117168_bib26","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1073\/pnas.0701297104","article-title":"Structural insights into the degradation of mcl-1 induced by BH3 domains","volume":"104","author":"Czabotar","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/acs.jmedchem.9b00983","article-title":"Hot-spots of mcl-1 protein","volume":"63","author":"Denis","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113038","article-title":"Development of mcl-1 inhibitors for cancer therapy","volume":"210","author":"Negi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114184","article-title":"Trends in targeting bcl-2 anti-apoptotic proteins for cancer treatment","volume":"232","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"49","key":"10.1016\/j.ejmech.2024.117168_bib30","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6195-y","article-title":"GX15\u2013070 (obatoclax), a bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases chemosensitivity in neuroblastoma","volume":"19","author":"Cournoyer","year":"2019","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.ejmech.2024.117168_bib32","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/jm030190z","article-title":"Discovery, characterization, and Structure\u2212Activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte\/leukemia-2 proteins","volume":"46","author":"Kitada","year":"2003","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/JTO.0b013e3181d6e08e","article-title":"AT-101, a pan-bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer","volume":"5","author":"Moretti","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib34","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/JTO.0b013e31822e2941","article-title":"A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chembiol.2004.02.020","article-title":"Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting bcl-XL","volume":"11","author":"Becattini","year":"2004","journal-title":"Chem. Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib36","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"An optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"Wei","year":"2010","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2024.117168_bib37","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm060460o","article-title":"Structure-based design of potent small-molecule inhibitors of anti-apoptotic bcl-2 proteins","volume":"49","author":"Wang","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib38","doi-asserted-by":"crossref","DOI":"10.1039\/D2MD00095D","article-title":"Scaffold hopping from indoles to indazoles yields dual MCL-1\/BCL-2 inhibitors from MCL-1 selective leads","author":"Drennen","year":"2022","journal-title":"RSC Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2024.117168_bib39","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1021\/jm401170c","article-title":"Discovery of potent mcl-1\/bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins","volume":"56","author":"Tanaka","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/jm301448p","article-title":"Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design","volume":"56","author":"Friberg","year":"2013","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117168_bib42","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1021\/jm501984f","article-title":"Discovery of tricyclic indoles that potently inhibit mcl-1 using fragment-based methods and structure-based design","volume":"58","author":"Burke","year":"2015","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib43","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/acs.jmedchem.5b01660","article-title":"Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods","volume":"59","author":"Pelz","year":"2016","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/1873-3468.12497","article-title":"Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors","volume":"591","author":"Lee","year":"2017","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117168_bib45","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1021\/acs.jmedchem.7b01155","article-title":"Optimization of potent and selective tricyclic indole diazepinone myeloid cell leukemia-1 inhibitors using structure-based design","volume":"61","author":"Shaw","year":"2018","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117168_bib46","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1021\/acs.jmedchem.8b01991","article-title":"Discovery of potent myeloid cell leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer","volume":"62","author":"Lee","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117168_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1025305520585","article-title":"Ligand binding to domain-3 of human serum albumin: a chemometric analysis","volume":"17","author":"Hajduk","year":"2003","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib48","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib49","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/jm501258m","article-title":"Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity","volume":"58","author":"Bruncko","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib50","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Leverson","year":"2015","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib51","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/10428194.2019.1622098","article-title":"Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells","volume":"60","author":"Chen","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib52","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117168_bib53","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1080\/10428194.2018.1563694","article-title":"MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can Be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells","volume":"60","author":"Wang","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2024.117168_bib54","article-title":"Development of a series of novel mcl-1 inhibitors bearing an indole carboxylic acid moiety","volume":"106018","author":"Deng","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117168_bib55","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1021\/acs.jmedchem.3c00134","article-title":"Macrocycles in drug Discovery\u2500Learning from the past for the future","volume":"66","author":"Garcia Jimenez","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116234","article-title":"Macrocycles and macrocyclization in anticancer drug discovery: important pieces of the puzzle","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib58","author":"Hargreaves"},{"key":"10.1016\/j.ejmech.2024.117168_bib59","article-title":"Targeting myeloid leukemia-1 in cancer therapy: advances and directions","author":"Deng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib60","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib61","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4155\/fmc.12.93","article-title":"Macrocycles in new drug discovery","volume":"4","author":"Mallinson","year":"2012","journal-title":"Future Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib62","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1016\/j.apsb.2022.09.022","article-title":"Harnessing the cyclization strategy for new drug discovery","volume":"12","author":"Tang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.ejmech.2024.117168_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-023-00836-z","article-title":"A PKPD case study: achieving clinically relevant exposures of AZD5991 in oncology mouse models","volume":"25","author":"White","year":"2023","journal-title":"AAPS J."},{"issue":"Supplement 1","key":"10.1016\/j.ejmech.2024.117168_bib64","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1182\/blood-2022-158620","article-title":"Combined inhibition of MCL1 By AZD5991 and BCL2\/bclxl by AZD4320 as promising strategies to overcome acute leukemia tumor burden and niche chemoresistance","volume":"140","author":"Bueno","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117168_bib65","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.3c00141","article-title":"Macrocyclic carbon-linked pyrazoles as novel inhibitors of MCL-1","author":"Demin","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117168_bib66","author":"Rombouts"},{"issue":"14","key":"10.1016\/j.ejmech.2024.117168_bib67","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1021\/acscatal.2c02090","article-title":"Synthesis of atropisomeric biaryls via chiral suzuki\u2013miyaura\/enzymatic kinetic resolution","volume":"12","author":"Jouffroy","year":"2022","journal-title":"ACS Catal."},{"issue":"12_Supplement","key":"10.1016\/j.ejmech.2024.117168_bib68","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/1538-7445.AM2022-2133","article-title":"Abstract 2133: in pursuit of MCL-1 inhibitors with improved therapeutic window for the treatment of hematological malignancies: discovery of JNJ-4355","volume":"82","author":"Rombouts","year":"2022","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib69","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"issue":"16_Supplement","key":"10.1016\/j.ejmech.2024.117168_bib70","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","article-title":"Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor","volume":"80","author":"Caenepeel","year":"2020","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.ejmech.2024.117168_bib71","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1021\/acs.jmedchem.9b01310","article-title":"Discovery and in vivo evaluation of macrocyclic mcl-1 inhibitors featuring an \u03b1-hydroxy phenylacetic acid pharmacophore or bioisostere","volume":"62","author":"Rescourio","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib72","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c01953","article-title":"Discovery of an oral, beyond-rule-of-five mcl-1 protein\u2013protein interaction modulator with the potential of treating hematological malignancies","author":"Romanov-Michailidis","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib73","author":"Rombouts"},{"key":"10.1016\/j.ejmech.2024.117168_bib74","author":"Chu"},{"key":"10.1016\/j.ejmech.2024.117168_bib75","author":"Zhuo"},{"issue":"13_Supplement","key":"10.1016\/j.ejmech.2024.117168_bib76","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1538-7445.AM2021-983","article-title":"Abstract 983: preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1","volume":"81","author":"Bhagwat","year":"2021","journal-title":"Cancer Res."},{"issue":"12_Supplement","key":"10.1016\/j.ejmech.2024.117168_bib77","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/1538-7445.AM2022-420","article-title":"Abstract 420: combination of the MCL1 inhibitor PRT1419 and SMARCA2 degrader PRT3789 shows combinatorial benefit in SMARCA4 deleted lung cancer","volume":"82","author":"Fultang","year":"2022","journal-title":"Cancer Res."},{"issue":"8_Supplement","key":"10.1016\/j.ejmech.2024.117168_bib78","doi-asserted-by":"crossref","first-page":"CT172","DOI":"10.1158\/1538-7445.AM2023-CT172","article-title":"Abstract CT172: a phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors","volume":"83","author":"Falchook","year":"2023","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib79","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1021\/acsomega.9b00611","article-title":"Establishing drug discovery and identification of hit series for the anti-apoptotic proteins, bcl-2 and mcl-1","volume":"4","author":"Murray","year":"2019","journal-title":"ACS Omega"},{"issue":"15","key":"10.1016\/j.ejmech.2024.117168_bib80","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1021\/acs.jmedchem.9b00134","article-title":"Structure-guided discovery of a selective mcl-1 inhibitor with cellular activity","volume":"62","author":"Szl\u00e1vik","year":"2019","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2024.117168_bib81","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a potent and selective mcl-1 inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med. Chem."},{"issue":"7626","key":"10.1016\/j.ejmech.2024.117168_bib82","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.ejmech.2024.117168_bib83","doi-asserted-by":"crossref","first-page":"15562","DOI":"10.1021\/acs.joc.3c00939","article-title":"Enabling, decagram-scale synthesis of macrocyclic MCL-1 inhibitor ABBV-467","volume":"88","author":"Brady","year":"2023","journal-title":"J. Org. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-023-00380-z","article-title":"Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients","volume":"3","author":"Yuda","year":"2023","journal-title":"Commun. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117168_bib85","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/ol702952n","article-title":"The marinopyrroles, antibiotics of an unprecedented structure class from a marine Streptomyces sp","volume":"10","author":"Hughes","year":"2008","journal-title":"Org. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib86","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1021\/jo1002054","article-title":"Structures, reactivities, and antibiotic properties of the marinopyrroles A\u2212F","volume":"75","author":"Hughes","year":"2010","journal-title":"J. Org. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117168_bib87","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/cc100052j","article-title":"Total synthesis of (\u00b1)-Marinopyrrole A and its library as potential antibiotic and anticancer agents","volume":"12","author":"Cheng","year":"2010","journal-title":"J. Comb. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.117168_bib88","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1074\/jbc.M111.334532","article-title":"Discovery of marinopyrrole A (Maritoclax) as a selective mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting mcl-1 for proteasomal degradation","volume":"287","author":"Doi","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib89","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/md12031335","article-title":"Cyclic marinopyrrole derivatives as disruptors of mcl-1 and bcl-xL binding to bim","volume":"12","author":"Cheng","year":"2014","journal-title":"Mar. Drugs"},{"issue":"8","key":"10.1016\/j.ejmech.2024.117168_bib90","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.3390\/md12084311","article-title":"Marinopyrrole derivatives with sulfide spacers as selective disruptors of mcl-1 binding to pro-apoptotic protein bim","volume":"12","author":"Cheng","year":"2014","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2024.117168_bib91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2014.11.035","article-title":"Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of mcl-1 binding to pro-apoptotic bim and dual mcl-1\/bcl-xL inhibitors","volume":"90","author":"Li","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib92","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1021\/jm500010b","article-title":"3-Substituted-N-(4-Hydroxynaphthalen-1-Yl)Arylsulfonamides as a novel class of selective mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation","volume":"57","author":"Abulwerdi","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib93","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1535-7163.MCT-12-0767","article-title":"A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo","volume":"13","author":"Abulwerdi","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib94","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1038\/s41467-020-19547-6","article-title":"Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an alzheimer's disease mouse model","volume":"11","author":"Cen","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2024.117168_bib95","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cmdc.201400058","article-title":"Development of 3-phenyl-N-(2-(3-Phenylureido)Ethyl)-Thiophene-2-Sulfonamide compounds as inhibitors of antiapoptotic bcl-2 family proteins","volume":"9","author":"Yang","year":"2014","journal-title":"ChemMedChem"},{"issue":"14","key":"10.1016\/j.ejmech.2024.117168_bib96","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1021\/acs.jmedchem.1c00690","article-title":"Structure-based optimization of 3-phenyl-N-(2-(3-Phenylureido)Ethyl)Thiophene-2-Sulfonamide derivatives as selective mcl-1 inhibitors","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2024.117168_bib97","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1021\/acs.jmedchem.1c00682","article-title":"Discovery of 3,5-dimethyl-4-sulfonyl-1H-Pyrrole-Based myeloid cell leukemia 1 inhibitors with high affinity, selectivity, and oral bioavailability","volume":"64","author":"Zhu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117168_bib98","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib99","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nchembio.2174","article-title":"Inhibition of mcl-1 through covalent modification of a noncatalytic lysine side chain","volume":"12","author":"Ak\u00e7ay","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.117168_bib100","article-title":"2-Ethynylbenzaldehyde-Based, lysine-targeting irreversible covalent inhibitors for protein kinases and nonkinases","author":"Chen","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117168_bib101","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1021\/acs.jmedchem.1c00005","article-title":"Design, synthesis, and structural characterization of lysine covalent BH3 peptides targeting mcl-1","volume":"64","author":"Gambini","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib102","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c00277","article-title":"Histidine-covalent stapled alpha-helical peptides targeting hMcl-1","author":"Alboreggia","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib103","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.202100011","article-title":"Drimane derivatives as the first examples of covalent BH3 mimetics that target MCL\u20101","volume":"16","author":"Daressy","year":"2021","journal-title":"ChemMedChem"},{"issue":"31","key":"10.1016\/j.ejmech.2024.117168_bib104","doi-asserted-by":"crossref","first-page":"12274","DOI":"10.1021\/jacs.9b03623","article-title":"Chemoselective peptide cyclization and bicyclization directly on unprotected peptides","volume":"141","author":"Zhang","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117168_bib105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/acs.biochem.9b00787","article-title":"OPA-based bifunctional linker for protein labeling and profiling","volume":"59","author":"Zhang","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2024.117168_bib106","article-title":"A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions","author":"Guo","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113546","article-title":"NA1\u2014115\u20147, from Zygogynum Pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes","volume":"154","author":"Daressy","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117168_bib108","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nsmb.3223","article-title":"Allosteric inhibition of antiapoptotic MCL-1","volume":"23","author":"Lee","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chempr.2019.10.013","article-title":"Classification of metal-based drugs according to their mechanisms of action","volume":"6","author":"Boros","year":"2020","journal-title":"Chem"},{"issue":"13","key":"10.1016\/j.ejmech.2024.117168_bib110","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1039\/D1CS00933H","article-title":"Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases","volume":"51","author":"Lu","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117168_bib111","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ncb2488","article-title":"Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration","volume":"14","author":"Perciavalle","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.117168_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111567","article-title":"Discovery of \u03b2-carboline copper(II) complexes as mcl-1 inhibitor and in vitro and in vivo activity in cancer models","volume":"181","author":"Lu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2024.117168_bib113","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/acs.jmedchem.9b02047","article-title":"Discovery of a copper-based mcl-1 inhibitor as an effective antitumor agent","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib114","article-title":"Platinum-based mcl-1 inhibitor targeting mitochondria achieves enhanced antitumor activity as a single agent or in combination with ABT-199","author":"Lu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib115","doi-asserted-by":"crossref","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","author":"Liu","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"15","key":"10.1016\/j.ejmech.2024.117168_bib116","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the skp1\u2013cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib117","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib118","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.9b00455","article-title":"From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1)","volume":"62","author":"Papatzimas","year":"2019","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2024.117168_bib119","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/cbic.201800380","article-title":"Proteome-wide identification of on- and off-targets of bcl-2 inhibitors in native biological systems by using affinity-based probes (AfBPs)","volume":"19","author":"Wang","year":"2018","journal-title":"Chembiochem"},{"issue":"17","key":"10.1016\/j.ejmech.2024.117168_bib120","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1021\/acs.jmedchem.9b00919","article-title":"Proteolysis targeting chimeras for the selective degradation of mcl-1\/bcl-2 derived from nonselective target binding ligands","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib122","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib123","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/bloodadvances.2020003624","article-title":"Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma","volume":"5","author":"Spaan","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-04154-0","article-title":"Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells","volume":"12","author":"Malyukova","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2024.117168_bib125","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1182\/blood-2019-129052","article-title":"MCL-1 inhibition by the selective MCL-1 inhibitor AMG-176 induces in vitro activity against Burkitt lymphoma cell lines and synergistically enhances the cytotoxic effect of chemotherapy and BH3 mimetics","volume":"134","author":"Daly","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejmech.2024.117168_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2646-2","article-title":"MCL1 inhibitors S63845\/mik665 plus navitoclax synergistically kill difficult-to-treat melanoma cells","volume":"11","author":"Mukherjee","year":"2020","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117168_bib127","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib128","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13492","article-title":"Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML","volume":"105","author":"Hormi","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"15","key":"10.1016\/j.ejmech.2024.117168_bib129","doi-asserted-by":"crossref","first-page":"8092","DOI":"10.3390\/ijms22158092","article-title":"Rationale for a combination therapy with the STAT5 inhibitor AC-4-130 and the MCL1 inhibitor S63845 in the treatment of FLT3-mutated or TET2-mutated acute myeloid leukemia","volume":"22","author":"Seipel","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.ejmech.2024.117168_bib130","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib131","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-all","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Advances"},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib132","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/cancers11111779","article-title":"Rationale for a combination therapy consisting of MCL1- and MEK-inhibitors in acute myeloid leukemia","volume":"11","author":"Seipel","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib133","first-page":"1","article-title":"MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment","volume":"8","author":"Alcon","year":"2022","journal-title":"Cell Death Dis."},{"issue":"401","key":"10.1016\/j.ejmech.2024.117168_bib134","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7049","article-title":"Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer","volume":"9","author":"Merino","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.117168_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101313","article-title":"Co-targeting MCL-1 and ERK1\/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"16","author":"Winkler","year":"2022","journal-title":"Translational Oncology"},{"issue":"12","key":"10.1016\/j.ejmech.2024.117168_bib136","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/2159-8290.CD-18-0277","article-title":"Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS -mutant non\u2013small cell lung cancer","volume":"8","author":"Nangia","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117168_bib137","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2021-151062","article-title":"Dual targeting bcl-2 By venetoclax and Mcl-1 By AZD5991 to overcome therapeutic resistance in aggressive R\/R mantle cell lymphoma","volume":"138","author":"Li","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejmech.2024.117168_bib138","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","article-title":"C-myc plays a critical role in the antileukemic activity of the mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia","volume":"27","author":"Liu","year":"2022","journal-title":"Apoptosis"},{"issue":"17","key":"10.1016\/j.ejmech.2024.117168_bib139","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3390\/cells11172752","article-title":"Inhibition of mcl-1 synergistically enhances the antileukemic activity of gilteritinib and MRX-2843 in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"11","author":"Wu","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117168_bib140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbrc.2018.09.009","article-title":"Degron mediated BRM\/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1\/SMARCA4-mutant cancers","volume":"508","author":"Rago","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117168_bib141","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.3390\/ijms24054961","article-title":"Enhanced apoptosis and loss of cell viability in melanoma cells by combined inhibition of ERK and mcl-1 is related to loss of mitochondrial membrane potential, caspase activation and upregulation of proapoptotic bcl-2 proteins","volume":"24","author":"Peng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.117168_bib142","first-page":"2024","article-title":"Engineering BCMA CAR T cells for myeloma-targeted cargo delivery","volume":"17","author":"Kimman","year":"2024","journal-title":"bioRxiv February"},{"issue":"32","key":"10.1016\/j.ejmech.2024.117168_bib143","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1021\/acs.biochem.8b00626","article-title":"Understanding the species selectivity of myeloid cell leukemia-1 (Mcl-1) inhibitors","volume":"57","author":"Zhao","year":"2018","journal-title":"Biochemistry"},{"issue":"15","key":"10.1016\/j.ejmech.2024.117168_bib144","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","article-title":"Humanized mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use","volume":"132","author":"Brennan","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.ejmech.2024.117168_bib145","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1021\/acs.jmedchem.8b00666","article-title":"Design and characterization of novel covalent bromodomain and extra-terminal domain (BET) inhibitors targeting a methionine","volume":"61","author":"Kharenko","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117168_bib146","first-page":"1","article-title":"Strain-release alkylation of Asp 12 enables mutant selective targeting of K-Ras-G12D","author":"Zheng","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.117168_bib147","article-title":"Chemoselective covalent modification of K-Ras(G12R) with a small molecule electrophile","author":"Zhang","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib148","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic peptides as drug candidates: recent progress and remaining challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117168_bib149","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202308251","article-title":"Cyclic peptides for drug development","volume":"63","author":"Ji","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"issue":"44","key":"10.1016\/j.ejmech.2024.117168_bib150","doi-asserted-by":"crossref","first-page":"15904","DOI":"10.1002\/anie.201908713","article-title":"A genetically encoded, phage-displayed cyclic-peptide library","volume":"58","author":"Wang","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117168_bib151","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsmedchemlett.6b00464","article-title":"Structure based design of non-natural peptidic macrocyclic mcl-1 inhibitors","volume":"8","author":"Johannes","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"6694","key":"10.1016\/j.ejmech.2024.117168_bib152","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1126\/science.adk1687","article-title":"Expansive discovery of chemically diverse structured macrocyclic oligoamides","volume":"384","author":"Salveson","year":"2024","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejmech.2024.117168_bib23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"21","author":"Maurer","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2024.117168_bib153","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.0c05537","article-title":"Phosphorylation-inducing chimeric small molecules","author":"Siriwardena","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.117168_bib154","doi-asserted-by":"crossref","DOI":"10.1021\/acscentsci.3c00200","article-title":"Development and applications of chimera platforms for tyrosine phosphorylation","author":"Pergu","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117168_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105064","article-title":"Small molecule SJ572946 activates BAK to initiate apoptosis","volume":"25","author":"Sekar","year":"2022","journal-title":"iScience"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342401050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342401050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:02:10Z","timestamp":1741287730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342401050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":154,"alternative-id":["S022352342401050X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117168","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical dissection of selective myeloid leukemia-1 inhibitors: How they were found and evolved","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117168"}}